» Articles » PMID: 35167623

DNAJB1-PRKACA in HEK293T Cells Induces LINC00473 Overexpression That Depends on PKA Signaling

Abstract

Fibrolamellar carcinoma (FLC) is a primary liver cancer that most commonly arises in adolescents and young adults in a background of normal liver tissue and has a poor prognosis due to lack of effective chemotherapeutic agents. The DNAJB1-PRKACA gene fusion (DP) has been reported in the majority of FLC tumors; however, its oncogenic mechanisms remain unclear. Given the paucity of cellular models, in particular FLC tumor cell lines, we hypothesized that engineering the DP fusion gene in HEK293T cells would provide insight into the cellular effects of the fusion gene. We used CRISPR/Cas9 to engineer HEK293T clones expressing DP fusion gene (HEK-DP) and performed transcriptomic, proteomic, and mitochondrial studies to characterize this cellular model. Proteomic analysis of DP interacting partners identified mitochondrial proteins as well as proteins in other subcellular compartments. HEK-DP cells demonstrated significantly elevated mitochondrial fission, which suggests a role for DP in altering mitochondrial dynamics. Transcriptomic analysis of HEK-DP cells revealed a significant increase in LINC00473 expression, similar to what has been observed in primary FLC samples. LINC00473 overexpression was reversible with siRNA targeting of PRKACA as well as pharmacologic targeting of PKA and Hsp40 in HEK-DP cells. Therefore, our model suggests that LINC00473 is a candidate marker for DP activity.

Citing Articles

DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.

Ma R, Tsai P, Farghli A, Shumway A, Kanke M, Gordan J PLoS Genet. 2024; 20(3):e1011216.

PMID: 38512964 PMC: 11020935. DOI: 10.1371/journal.pgen.1011216.


Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.

Du L, Wilson B, Li N, Shah R, Dalilian M, Wang D J Nat Prod. 2023; 86(10):2283-2293.

PMID: 37843072 PMC: 10616853. DOI: 10.1021/acs.jnatprod.3c00394.


The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway.

Bolger G Front Endocrinol (Lausanne). 2022; 13:1024423.

PMID: 36313756 PMC: 9612118. DOI: 10.3389/fendo.2022.1024423.


Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.

Francisco A, Kanke M, Massa A, Dinh T, Sritharan R, Vakili K JCI Insight. 2022; 7(11).

PMID: 35482409 PMC: 9220943. DOI: 10.1172/jci.insight.154743.


A framework for fibrolamellar carcinoma research and clinical trials.

Dinh T, Utria A, Barry K, Ma R, Abou-Alfa G, Gordan J Nat Rev Gastroenterol Hepatol. 2022; 19(5):328-342.

PMID: 35190728 PMC: 9516439. DOI: 10.1038/s41575-022-00580-3.

References
1.
Meng X, Kong D, Li N, Zong Z, Liu B, Du Z . Knockdown of BAG3 induces epithelial-mesenchymal transition in thyroid cancer cells through ZEB1 activation. Cell Death Dis. 2014; 5:e1092. PMC: 3944249. DOI: 10.1038/cddis.2014.32. View

2.
Takayama S, Bimston D, Matsuzawa S, Freeman B, Aime-Sempe C, Xie Z . BAG-1 modulates the chaperone activity of Hsp70/Hsc70. EMBO J. 1997; 16(16):4887-96. PMC: 1170124. DOI: 10.1093/emboj/16.16.4887. View

3.
Weeda V, Murawski M, McCabe A, Maibach R, Brugieres L, Roebuck D . Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma--results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013; 49(12):2698-704. DOI: 10.1016/j.ejca.2013.04.012. View

4.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

5.
Kwan J, Sczaniecka A, Heidary Arash E, Nguyen L, Chen C, Ratkovic S . DLG5 connects cell polarity and Hippo signaling protein networks by linking PAR-1 with MST1/2. Genes Dev. 2017; 30(24):2696-2709. PMC: 5238729. DOI: 10.1101/gad.284539.116. View